Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 500 Shares of Company Stock

Key Points

• Insider sale: Sarah Gheuens sold 500 Agios Pharmaceuticals shares at an average of $37.52, generating $18,760. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left her with 54,645 shares.
• Stock and financial performance: AGIO recently traded near $37, with a market capitalization of $2.21 billion. The company reported a quarterly loss of $1.69 per share, missing estimates, although revenue of $44.75 million exceeded expectations.
• Analyst outlook: Agios has a consensus “Moderate Buy” rating and an average price target of $41.50, despite ratings ranging from Sell to Strong Buy.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 500 shares of the stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $37.52, for a total transaction of $18,760.00. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at $2,050,280.40. This trade represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.53, for a total value of $55,882.17.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Price Performance

Shares of AGIO traded down $0.19 during mid-day trading on Friday, reaching $37.00. 920,048 shares of the company's stock traded hands, compared to its average volume of 1,059,158. The stock has a market cap of $2.21 billion, a P/E ratio of -5.28 and a beta of 0.63. The stock's 50-day moving average is $33.34 and its two-hundred day moving average is $32.76. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The business had revenue of $44.75 million during the quarter, compared to analysts' expectations of $26.39 million. Research analysts predict that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Citigroup increased their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. HC Wainwright lifted their target price on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Weiss Ratings reissued a "sell (d)" rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. Truist Financial cut their price target on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a "buy" rating on the stock in a report on Wednesday, October 7th. Finally, TD Cowen raised shares of Agios Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.50.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Nykredit A S purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $26,000. Quantinno Capital Management LP grew its stake in Agios Pharmaceuticals by 2.7% in the first quarter. Quantinno Capital Management LP now owns 27,591 shares of the biopharmaceutical company's stock worth $933,000 after purchasing an additional 736 shares in the last quarter. AlphaCentric Advisors LLC increased its holdings in Agios Pharmaceuticals by 6.3% during the 1st quarter. AlphaCentric Advisors LLC now owns 13,971 shares of the biopharmaceutical company's stock worth $473,000 after purchasing an additional 830 shares during the period. Inspire Investing LLC increased its holdings in Agios Pharmaceuticals by 4.7% during the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company's stock worth $636,000 after purchasing an additional 861 shares during the period. Finally, Quantbot Technologies LP purchased a new position in Agios Pharmaceuticals during the 2nd quarter worth $43,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company's research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.